XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2020 $ 11,061 $ 57 $ 27,443 $ (10,946) $ (2,399) $ (4,128) $ 10,026 $ 1,035
Beginning balance, shares at Dec. 31, 2020   1,202            
Net income (loss) 456     417     417 39
Other comprehensive income (loss) (391)       (283)   (283) (107)
Issuance of Shares, shares   7            
Stock-based compensation expense 119   119       119  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2021 11,244 $ 57 27,561 (10,529) (2,683) (4,128) 10,278 966
Ending balance, shares at Dec. 31, 2021   1,209            
Net income (loss) (2,499)     (2,446)     (2,446) (53)
Other comprehensive income (loss) (270)       (154)   (154) (116)
Issuance of Shares, value 1   1       1  
Issuance of Shares, shares   8            
Stock-based compensation expense 124   124       124  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2022 8,598 $ 57 27,688 (12,975) (2,838) (4,128) 7,804 794
Ending balance, shares at Dec. 31, 2022   1,217            
Beginning balance at Jun. 30, 2022 9,810              
Net income (loss) 63              
Ending balance at Sep. 30, 2022 9,506              
Net income (loss) (1,333)              
Ending balance at Dec. 31, 2022 8,598 $ 57 27,688 (12,975) (2,838) (4,128) 7,804 794
Ending balance, shares at Dec. 31, 2022   1,217            
Net income (loss) (253)              
Ending balance at Mar. 31, 2023 8,504              
Beginning balance at Dec. 31, 2022 8,598 $ 57 27,688 (12,975) (2,838) (4,128) 7,804 794
Beginning balance, shares at Dec. 31, 2022   1,217            
Net income (loss) (615)     (559)     (559) (56)
Other comprehensive income (loss) 91       141   141 (50)
Issuance of Shares, shares   10            
Stock-based compensation expense 121   121       121  
Dividend to non-controlling interests [1] (68)             (68)
Ending balance at Dec. 31, 2023 8,126 $ 57 27,807 (13,534) (2,697) (4,128) 7,506 620
Ending balance, shares at Dec. 31, 2023   1,227            
Beginning balance at Mar. 31, 2023 8,504              
Net income (loss) (905)              
Ending balance at Jun. 30, 2023 7,592              
Net income (loss) 78              
Ending balance at Sep. 30, 2023 7,387              
Ending balance at Dec. 31, 2023 $ 8,126 $ 57 $ 27,807 $ (13,534) $ (2,697) $ (4,128) $ 7,506 $ 620
Ending balance, shares at Dec. 31, 2023   1,227            
[1] Mainly in connection with a declaration of dividends to non-controlling interests in Teva’s joint venture in Japan.